Description: Ceftobiprole (Ro-63-9141; BAL 9141) is a fifth-generation and broad-spectrum cephalosporin prodrug for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae, to penicillin-binding protein 2x in Streptococcus pneumoniae, and to penicillin-binding protein 5 in Enterococcus faecalis.
References:
[1].Kisgen J, et al. Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-ResistantStaphylococcus aureus(MRSA). P T. 2008 Nov;33(11):631-41.
[2].Hodille E, et al. In vitro activity of ceftobiprole on 440Staphylococcus aureusstrains isolated from bronchopulmonary infections. Med Mal Infect. 2017 Mar;47(2):152-157.
[3]. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015 Aug 18;9:4565-72. doi: 10.2147/DDDT.S56616. eCollection 2015.